Literature DB >> 14567160

[Survey of management methods for patients in a state of agitation at admission and emergency departments in France].

V Bourdinaud1, F Pochard.   

Abstract

UNLABELLED: The increasing prevalence of the agitation states in the emergency department (ED) is a problem little studied on the epidemiological plan.
OBJECTIVE: To define the prevalence of the agitation states in the ED in France, to determine predicative criteria of the agitation states to prevent a potentially dangerous situation and take care as fast as possible of it, to know current practices in front of these situations, and to collect the recommendations of the departmental managers of the ED to improve this management.
METHOD: A questionnaire of appraisal was sent to the 464 managers of the ED of hospitals and clinics in metropolitan France, containing 21 questions.
RESULTS: 137 (29.5%) departmental managers answered. The average of admittances by ED is 24,000 a year. The estimated prevalence of the number of situations of agitation represents 1.22% of the total of admittances. The average prevalence a month and by service of verbal attacks is 36.3, that of the physical attacks is 1.14. The number of attacks (and their consequences) correlate with admittances by ED. The intervention of the police is required on average 17 times a year and by ED. Only 29.5% of the ED consider to have premises adapted for the management of the agitated patients; 32.3% of the ED have a protocol established for the agitation states; 16.3% of services accumulate a protocol and a training of the professionals; 10.5% of establishments have at the same moment adapted premises, a protocol and a forming of the staff for the management of the agitated patients. Among the agitated patients, those that profit by a sedation represent on average 67.7% and it varies according to ED. The sedative treatment used in first intention is loxapine in intramuscular injection for 84% of them. The predicative factors identified of agitation states are intoxications, mainly the alcohol (88%) and the poly drug addiction (46.3%). More than half of the ED recommend in a systematic way and for lack of diagnostic orientation the dosages of alcohol, drugs, glycaemia and bloody electrolytes; 85% of the departmental managers consider that a better management of the agitation states rests on the presence of adapted premises and on a specific forming of the nursing staff.
CONCLUSION: The management of the agitated patients in the ED requires the placing of protocols and of specific trainings as well as of adapted premises. The major prevalence of attacks imposes realization of epidemiological studies and the priority placing of a coherent politics, considering the potential and often real gravity of these behavioural problems.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14567160

Source DB:  PubMed          Journal:  Encephale        ISSN: 0013-7006            Impact factor:   1.291


  9 in total

Review 1.  Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review.

Authors:  Diane Merino; Arnaud Fernandez; Alexandre O Gérard; Nouha Ben Othman; Fanny Rocher; Florence Askenazy; Céline Verstuyft; Milou-Daniel Drici; Susanne Thümmler
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-14

2.  Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.

Authors:  Nicholas Gross; Leon S Greos; Eli O Meltzer; Selwyn Spangenthal; Robert S Fishman; Daniel A Spyker; James V Cassella
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-12       Impact factor: 2.849

3.  Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens.

Authors:  Daniel A Spyker; Robert A Riesenberg; James V Cassella
Journal:  J Clin Pharmacol       Date:  2015-05-06       Impact factor: 3.126

4.  State of Acute Agitation at Psychiatric Emergencies in Europe: The STAGE Study.

Authors:  Luis San; Josef Marksteiner; Peter Zwanzger; María Aragüés Figuero; Francisco Toledo Romero; Grigorios Kyropoulos; Alberto Bessa Peixoto; Roxana Chirita; Anca Boldeanu
Journal:  Clin Pract Epidemiol Ment Health       Date:  2016-10-27

5.  Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses.

Authors:  Scott Zeller; Leslie Zun; James V Cassella; Daniel A Spyker; Paul P Yeung
Journal:  BJPsych Open       Date:  2017-11-10

6.  Inhaled Loxapine as a Rapid Treatment for Agitation in Patients with Personality Disorder: A Prospective Study on the Effects of Time.

Authors:  Marc Ferrer; Óscar Soto-Angona; María Soler-Artigas; Pol Ibáñez; Christian Fadeuilhe; Raúl Felipe Palma-Álvarez; Raquefet Lidai; Sebastian Vargas-Cáceres; María Ángeles Torrecilla; Anna López; Josep Antoni Ramos-Quiroga
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-08-31       Impact factor: 3.731

7.  Actionable Predictive Factors of Homelessness in a Psychiatric Population: Results from the REHABase Cohort Using a Machine Learning Approach.

Authors:  Guillaume Lio; Malek Ghazzai; Frédéric Haesebaert; Julien Dubreucq; Hélène Verdoux; Clélia Quiles; Nemat Jaafari; Isabelle Chéreau-Boudet; Emilie Legros-Lafarge; Nathalie Guillard-Bouhet; Catherine Massoubre; Benjamin Gouache; Julien Plasse; Guillaume Barbalat; Nicolas Franck; Caroline Demily
Journal:  Int J Environ Res Public Health       Date:  2022-09-27       Impact factor: 4.614

8.  Issues in the management of acute agitation: how much current guidelines consider safety?

Authors:  Bruno Pacciardi; Mauro Mauri; Claudio Cargioli; Simone Belli; Biagio Cotugno; Luca Di Paolo; Stefano Pini
Journal:  Front Psychiatry       Date:  2013-05-07       Impact factor: 4.157

9.  Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting: protocol for a phase IV, single-arm, open-label trial.

Authors:  Emilio Gil; Fernando Garcia-Alonso; Anca Boldeanu; Thaïs Baleeiro Teixeira
Journal:  BMJ Open       Date:  2018-10-02       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.